Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Mar;51(4):947-950.
doi: 10.1007/s00259-023-06568-8.

Dosimetry for targeted radionuclide therapy in routine clinical practice: experts advice vs. clinical evidence

Arnaud Dieudonné  1   2 , Clément Bailly  3 , Florent Cachin  4 , Agathe Edet-Sanson  5 , Françoise Kraeber-Bodéré  3 , Sébastien Hapdey  5 , Charles Merlin  4 , Philippe Robin  6 , Pierre-Yves Salaun  6 , Paul Schwartz  7 , David Tonnelet  5 , Pierre Vera  5 , Frédéric Courbon  8 , Thomas Carlier  3
Affiliations
Editorial

Dosimetry for targeted radionuclide therapy in routine clinical practice: experts advice vs. clinical evidence

Arnaud Dieudonné et al. Eur J Nucl Med Mol Imaging. 2024 Mar.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Similar articles

See all similar articles

Cited by

References

    1. Sjögreen-Gleisner K et al. EFOMP policy statement NO. 19: dosimetry in nuclear medicine therapy – molecular radiotherapy. Physica Medica 2023; 103166. 10.1016/j.ejmp.2023.103166 - PubMed
    1. Chiesa C, et al. The conflict between treatment optimization and registration of radiopharmaceuticals with fixed activity posology in oncological nuclear medicine therapy. Eur J Nucl Med Mol Imaging. 2017;44(11):1783–1786. doi: 10.1007/s00259-017-3707-3. - DOI - PubMed
    1. Konijnenberg M, et al. EANM position paper on article 56 of the Council Directive 2013/59/Euratom (basic safety standards) for nuclear medicine therapy. Eur J Nucl Med Mol Imaging. 2021;48(1):67–72. doi: 10.1007/s00259-020-05038-9. - DOI - PMC - PubMed
    1. Kappadath SC, Mikell J, Balagopal A, Baladandayuthapani V, Kaseb A, Mahvash A. Hepatocellular carcinoma tumor dose response after 90Y-radioembolization with glass microspheres using 90Y-SPECT/CT-based voxel dosimetry. Int J Radiat Oncol Biol Phys. 2018;102(2):451–461. doi: 10.1016/j.ijrobp.2018.05.062. - DOI - PubMed
    1. Hermann A-L et al. Relationship of tumor radiation–absorbed dose to survival and response in hepatocellular carcinoma treated with transarterial radioembolization with 90 Y in the SARAH Study. Radiology 2020; 191606. 10.1148/radiol.2020191606 - PubMed

Publication types

LinkOut - more resources